share_log

Is Jafron Biomedical Co.,Ltd.'s (SZSE:300529) Recent Stock Performance Tethered To Its Strong Fundamentals?

Is Jafron Biomedical Co.,Ltd.'s (SZSE:300529) Recent Stock Performance Tethered To Its Strong Fundamentals?

是 Jafron Biomedical Co.,Ltd. 's(深交所代码:300529)最近的股票表现与其强劲的基本面息息相关?
Simply Wall St ·  2023/09/30 22:14

Jafron BiomedicalLtd's (SZSE:300529) stock is up by a considerable 5.2% over the past month. Since the market usually pay for a company's long-term fundamentals, we decided to study the company's key performance indicators to see if they could be influencing the market. Particularly, we will be paying attention to Jafron BiomedicalLtd's ROE today.

Jafron BiomedicallTD(深交所股票代码:300529)的股票在过去一个月中大幅上涨了5.2%。由于市场通常会为公司的长期基本面付出代价,因此我们决定研究公司的关键业绩指标,看看它们是否会影响市场。特别是,我们将关注Jafron Biomedicalltd今天的投资回报率。

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. Put another way, it reveals the company's success at turning shareholder investments into profits.

股本回报率或投资回报率是对公司增值和管理投资者资金的有效性的考验。换句话说,它揭示了公司成功地将股东投资转化为利润。

See our latest analysis for Jafron BiomedicalLtd

查看我们对 Jafron biomedicallTD 的最新分析

How Is ROE Calculated?

ROE 是如何计算的?

Return on equity can be calculated by using the formula:

股本回报率可以通过使用以下公式计算:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回报率 = 净利润(来自持续经营业务)÷ 股东权益

So, based on the above formula, the ROE for Jafron BiomedicalLtd is:

因此,根据上述公式,Jafron biomedicallTD 的投资回报率为:

13% = CN¥410m ÷ CN¥3.3b (Based on the trailing twelve months to June 2023).

13% = 4.1亿元人民币 ^33亿元人民币(基于截至2023年6月的过去十二个月)。

The 'return' is the income the business earned over the last year. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.13 in profit.

“回报” 是企业去年获得的收入。这意味着,每持有价值1元人民币的股东权益,该公司就会产生0.13元人民币的利润。

Why Is ROE Important For Earnings Growth?

为什么投资回报率对收益增长很重要?

So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.

到目前为止,我们已经了解到,投资回报率是衡量公司盈利能力的指标。然后,我们能够评估公司的收益增长潜力,具体取决于公司对这些利润进行再投资或 “保留” 了多少及其有效性。一般而言,在其他条件相同的情况下,股本回报率和利润留存率高的公司的增长率要高于不具有这些属性的公司。

Jafron BiomedicalLtd's Earnings Growth And 13% ROE

Jafron biomedicalltd 的收益增长和 13% 的投资回报率

At first glance, Jafron BiomedicalLtd seems to have a decent ROE. Further, the company's ROE is similar to the industry average of 11%. This probably goes some way in explaining Jafron BiomedicalLtd's moderate 18% growth over the past five years amongst other factors.

乍一看,Jafron biomedicalltd的投资回报率似乎不错。此外,该公司的投资回报率与11%的行业平均水平相似。除其他因素外,这可能在某种程度上解释了Jafron biomedicalltd在过去五年中温和增长18%。

As a next step, we compared Jafron BiomedicalLtd's net income growth with the industry and found that the company has a similar growth figure when compared with the industry average growth rate of 18% in the same period.

下一步,我们将Jafron Biomedicalltd的净收入增长与该行业进行了比较,发现该公司的增长数字与同期18%的行业平均增长率相似。

past-earnings-growth
SZSE:300529 Past Earnings Growth October 1st 2023
深交所股票代码:300529 过去的收益增长 2023 年 10 月 1 日

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. Is Jafron BiomedicalLtd fairly valued compared to other companies? These 3 valuation measures might help you decide.

赋予公司价值的基础在很大程度上与其收益增长息息相关。投资者应尝试确定收益的预期增长或下降(无论情况如何)是否被计入其中。然后,这可以帮助他们确定股票是为光明的未来还是黯淡的未来而配置。与其他公司相比,Jafron biomedicalltd 的估值是否公平?这三种估值衡量标准可能会帮助您做出决定。

Is Jafron BiomedicalLtd Making Efficient Use Of Its Profits?

Jafron biomedicalltd 是否在有效利用其利润?

The high three-year median payout ratio of 58% (or a retention ratio of 42%) for Jafron BiomedicalLtd suggests that the company's growth wasn't really hampered despite it returning most of its income to its shareholders.

Jafron Biomedicalltd的三年中位派息率为58%(或留存率为42%),这表明尽管该公司将大部分收入返还给了股东,但其增长并没有真正受到阻碍。

Additionally, Jafron BiomedicalLtd has paid dividends over a period of six years which means that the company is pretty serious about sharing its profits with shareholders. Based on the latest analysts' estimates, we found that the company's future payout ratio over the next three years is expected to hold steady at 47%. Still, forecasts suggest that Jafron BiomedicalLtd's future ROE will rise to 24% even though the the company's payout ratio is not expected to change by much.

此外,Jafron Biomedicalltd在六年内支付了股息,这意味着该公司非常认真地与股东分享利润。根据分析师的最新估计,我们发现该公司未来三年的派息率预计将稳定在47%。尽管如此,预测表明,Jafron Biomedicalltd的未来投资回报率将升至24%,尽管该公司的派息率预计不会有太大变化。

Conclusion

结论

Overall, we are quite pleased with Jafron BiomedicalLtd's performance. Especially the high ROE, Which has contributed to the impressive growth seen in earnings. Despite the company reinvesting only a small portion of its profits, it still has managed to grow its earnings so that is appreciable. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

总体而言,我们对Jafron biomedicalltd的表现非常满意。尤其是高投资回报率,这促成了收益的惊人增长。尽管该公司仅将其利润的一小部分再投资,但它仍然设法增长了收益,因此这是可观的。话虽如此,从分析师目前的估计来看,我们发现该公司的收益有望增强。这些分析师的预期是基于对该行业的广泛预期,还是基于公司的基本面?点击此处进入我们分析师对公司的预测页面。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?担心内容吗? 取得联系 直接和我们在一起。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之,华尔街在上述任何股票中都没有头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发